Updated 7 October 2026. Melanotan I and Melanotan II are synthetic melanocortin peptides promoted online for tanning. They are often confused with afamelanotide, an authorized medicine for a rare light-sensitivity disorder. Cosmetic “Melanotan” products sold online are not interchangeable with that regulated implant and are not approved tanning medicines.
Melanotan I, afamelanotide and Melanotan II
Melanotan I is commonly used as an informal name for peptides related to afamelanotide, an analogue of alpha-melanocyte-stimulating hormone. In the European Union, afamelanotide is authorized as the 16 mg implant Scenesse for prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It is prescribed and administered in specialist centres. This authorization does not cover cosmetic tanning products.
Melanotan II is a different, less selective melanocortin-receptor agonist. Early small human studies explored pigmentation and erectile responses, but development did not establish it as an approved tanning medicine. Nausea, flushing, yawning and spontaneous erections were reported even in controlled early research.
What changed in 2026?
In August 2026, Australia's Therapeutic Goods Administration reported laboratory testing of seized Melanotan II nasal sprays. Bottles carrying the same “30 mg” label were estimated to contain between 22 mg and 54 mg. This large variation illustrates why a label on an unapproved online product cannot confirm its dose or quality.
The TGA warns that Melanotan II tanning products are unapproved and can expose users to serious risks. FDA safety information also cites published case reports involving melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxicity and priapism. Case reports do not always prove causation, but they are important safety signals.
Skin changes and UV protection
Reports have described rapid darkening or appearance of moles during unregulated melanotan use. Any new, changing or unusual mole requires medical assessment. Increased pigmentation also does not replace broad-spectrum sunscreen, protective clothing, shade or avoidance of excessive UV exposure.
Why the approved medicine is different
- Scenesse has a defined active ingredient, dose, implant formulation and authorized indication.
- It is supplied through a regulated chain and used under specialist supervision.
- Online Melanotan I or II products may have unknown identity, strength, sterility and impurities.
- An approval for EPP cannot be extended to cosmetic tanning.
Sources
- European Medicines Agency: Scenesse (afamelanotide)
- TGA 2026 laboratory findings on Melanotan II products
- TGA safety advice on Melanotan products
- FDA safety information on Melanotan II
- 2026 systematic review of tanning products and adverse effects
This article is educational and does not provide medical advice. Peptara Lab materials are supplied strictly for laboratory research and are not for human use.
